Skip to main content
ENDO 2026 Main banner

Neuroendocrinology and Pituitary

ORF28-05 - Effect of CAM2029 on Long-Term Biochemical and Symptom Control in Patients with Acromegaly and IGF-I ≤2×ULN According to Prior Injectable Somatostatin Receptor Ligand Dose: Results from ACROINNOVA 2

Sunday, June 14, 2026
2:15 PM - 2:30 PM CT
Location: Room W183BC

Background
Many patients with acromegaly do not achieve biochemical control (insulin‑like growth factor I [IGF-I] ≤upper limit of normal [ULN]) or symptom remission with injectable somatostatin receptor ligands (SRLs) such as octreotide long acting repeatable (LAR) and lanreotide Autogel (ATG). CAM2029, a long‑acting octreotide subcutaneous depot approved for adults with acromegaly in Europe and the UK, has demonstrated improved biochemical control in patients with IGF-I ≤2×ULN on baseline SRL therapy. Here, we report the effect of CAM2029 in these patients by prior SRL dose in the ACROINNOVA 2 study.

Methods
Patients directly enrolled on day 1 of ACROINNOVA 2 (NCT04125836) had IGF-I ≤2×ULN on baseline SRLs. CAM2029 20 mg was administered every 4 weeks (W) (±1W) for 52W. The primary endpoint was long‑term safety; secondary endpoints included biochemical control rate (mean IGF-I ≤ULN per age and sex at W50/52) and symptom control (Acromegaly Index of Severity [AIS]; range 0–18, lower scores indicate better symptoms). Prior SRL dose was categorized as low (octreotide LAR 10 mg or lanreotide ATG 60 mg) or mid–high (octreotide LAR ≥20 mg or lanreotide ATG ≥90 mg).

Results
Of 81 directly enrolled patients, the observed biochemical control rate increased progressively with CAM2029 treatment from baseline (14.8% [12/81]) to W24 (34.7% [26/75]) and W50/52 (36.5% [27/74]). Symptoms improved from baseline to W52; mean AIS Overall Scores (standard deviation [SD]) reduced from baseline (4.4 [3.6], n=81) to W24 (3.5 [2.7], n=76) and W52 (3.3 [2.9], n=73).

Among the 70 patients who previously received mid–high dose baseline SRLs, the observed proportion of patients with biochemical control progressively increased from baseline (12.9% [9/70]) to W24 (29.7% [19/64]) and W50/52 (33.3% [21/63]). Mean AIS Overall Scores (SD) decreased from baseline (4.4 [3.5], n=70) to W24 (3.3 [2.6], n=65) and W52 (3.2 [2.8], n=62).

Eleven patients previously received low-dose baseline SRLs. Among these patients, the observed biochemical control rate increased from baseline (27.3% [3/11]) to W24 (63.6% [7/11]) and W50/52 (54.5% [6/11]). Mean AIS Overall Scores (SD) were stable between baseline (4.7 [4.2], n=11) and W24 (4.6 [3.4], n=11), with some improvement at W52 (3.6 [3.6], n=11).

Conclusion
CAM2029 at a standard dose of 20 mg every 4W improved both biochemical and symptom control in patients with acromegaly who had IGF-I ≤2×ULN on baseline injectable SRLs, regardless of prior SRL dose. These results support CAM2029 as an effective treatment option for acromegaly, including for patients previously escalated to high doses of octreotide LAR or lanreotide ATG.